Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 14/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10834735 | 0.80 | CA1 (0.48) | ESR2HTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL1715789 | 0.80 | CA1 (0.48) | ESR2HTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL5883365 | 0.79 | ESR2 (0.41) | ERN1ESR2LMNA | |
| SCHEMBL16055346 | 0.79 | ERN1 (0.56) | ERN1ESR2 | |
| SCHEMBL18717054 | 0.76 | ESR2 (0.41) | ERN1ESR2ALDH1A1LMNA | |
| SCHEMBL23752821 | 0.74 | ESR2 (0.45) | ESR2HTR2CALDH1A1LMNA | |
| SCHEMBL12766871 | 0.73 | ERN1 (0.58) | ERN1 | |
| SCHEMBL27551121 | 0.73 | ESR2 (0.53) | ESR2HTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL2788053 | 0.72 | ERN1 (0.78) | ERN1ALDH1A1LMNA | |
| SCHEMBL6758138 | 0.72 | CA1 (0.44) | ESR2HTR2AHTR2CHTR2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152206-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152206-A1 | IRE-1alpha INHIBITORS | XBP1, DDIT3, ERN1 | ERN1 3/4885ESR2 442/4885HTR2A 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.